Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

3 Months Ended

Mar. 31, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Components of Stock-Based Compensation Expenses

The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants for the three months ended March 31, 2014 and 2013, and from the period June 28, 2006 (date of inception) to date:

	For the three months ended March 31,				Period from June 28, 2006 (date of inception) to March 31,
($ in thousands)	2014		2013		2014
Employee awards	$	1,122	$	972	$	9,194
Non-employee awards		13		434		4,323
Non-employee warrants				117		1,032
Total stock-based compensation expense	$	1,135	$	1,523	$	14,549

Summary of Stock Option Activity

The following table summarizes stock option activity:

	Outstanding Options						Weighted
($ in thousands except per share amounts)	Number of Shares		Weighted Average Exercise Price		Total Weighted Average Intrinsic Value		Average Remaining Contractual Life (in years)
At December 31, 2013		3,117,777	$	4.31	$			8.36
Options granted
Options exercised		(256,745)		1.88		26
Options cancelled		(600,000)		4.39
At March 31, 2014		2,261,032	$	4.57	$			8.20
Options vested and expected to vest		2,261,032	$	4.57	$			8.20
Options vested and exercisable		1,492,699	$	4.24	$			7.82

Nonvested Restricted Stock Shares Activity

The following table summarizes restricted stock activity:

	Restricted Stock
	Number of Shares		Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2013		3,958,692	$	1.93
Restricted stock granted		4,343,692		2.69
Unvested balance at March 31, 2014		8,302,384	$	2.33